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Background: Durable polymers used for first-generation drug-eluting stents
potentially contribute to persistent inflammation and late stent thrombosis. BICARE
(Lepu Medical, Beijing, China) is a novel polymer-free stent system with nano
technology and elutes rapamycin (1.6μg/mm2) and probucol (0.8μg /mm2). The first
in man study aimed to evaluate the preliminary feasibility and safety of the BICARE
stent.
Methods: Patients with stable or unstable angina, or prior myocardial infarction (MI),
with single de novo native coronary stenosis < 30mm in length in vessel sizes ranging
from 2.5 to 4.0 mm were enrolled at a single institution. The primary endpoint was
target lesion failure (TLF) at 30-day defined as the composite of cardiac death, target-
vessel MI (Q and non-Q), or ischemia-driven target lesion revascularization. Secondary
endpoints include in-stent late lumen loss by quantitative coronary angiography and
proportion of uncovered or malapposed stent struts by Optical Coherence Tomography
(OCT) at 4-month, and TLF at 4, 12, 24 and 36-month follow-up.
Results: A total of 32 patients (age 55.7±8.7 years, male 62.5%, diabetes 18.8%) were
enrolled consecutively in 1 month. The average baseline reference vessel diameter is
2.85±0.48 mm and the lesion length is 15.0±5.6 mm. There was no TLF at 30-day. All
of the patients (100%) underwent angiographic follow-up at 4-month. The in-stent late
loss was 0.14±0.19 mm, and the in-segment binary restenosis rate was 3.1%,
respectively. The complete strut coverage was 98.2% by OCT with only 0.2% strut
malapposition at 4-month among 16751 analyzed struts. There was no TLF at 4-month.
Conclusion: The preliminary feasibility and safety of the BICARE dual-drug polymer-
free stent are demonstrated in the first in human study. OCT findings indicated excellent
stent strut coverage at 4-month. Further pivotal randomized trial will confirm if this
early results could translate into longer term safety and efficacy benefits.
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Background: Absorbable magnesium scaffolds (AMS) are attractive as they only leave
behind the healed, natural vessel, allowing restoration of vasoreactivity with the
potential for vessel remodelling once bio-absorbed. Using optical coherence
tomography (OCT), bioabsorption of a Drug Eluting Absorbable Magnesium Scaffold
(DREAMS) can be characterized in humans.
Methods: BIOSOLVE-I is a prospective, multicenter first in man trial with follow-up
investigations at 1, 6, 12, 24 and 36 months. Twenty-two patients were enrolled in
cohort 1 with an imaging follow-up at 6 months and 24 patients were enrolled in cohort
2 with an imaging follow-up at 12 months. A subgroup of the patients were investigated
by OCT. From the 22 patients enrolled in cohort 1, paired post-procedure and 6-month
follow-up OCT images are available for 4 patients. Additional 10 patients had a 6-
month follow-up OCT investigation only.
Results: The twenty-two subjects of cohort 1 included 16 males and 6 females with a
mean age of 65.8 ± 10.4 years ranging from 42 to 77 years. Hypertension (86.4%),
hyperlipidemia (81.8%), were the major cardiovascular risk factors and history of
myocardial infarction was present in 40.9% of the subjects. Type A (50.0%), Type B1
(45.5%) and Type B2 (4.5%) lesions were treated with a 3.25 / 16 mm (50.0%) or a
3.5 / 16 mm (50.0%) Evaluation of OCT images are ongoing and will be available
upon presentation.
Conclusion: Acute OCT investigation showed stent placement and visual appearance
that is similar to a permanent metallic stent. The 6-month follow-up OCT images
revealed continued degradation of the scaffold.
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Background: Durable polymers in 1st generation DES have been linked to local
coronary inflammation that could ultimately result in life-threatening adverse events.
Polymer-free DES systems have been developed as an attractive alternative to
minimize these undesired effects. We sought to assess the safety and efficacy of the
novel VESTAsync™ Eluting Stent (VES) combining a Cro-Co platform with a
nanothin-microporous hydroxyapatite surface coating impregnated with a polymer-
free low-dose of Sirolimus (55μg).
Methods: The Vestasync II trial is a randomized (2:1), double-blinded multicenter
comparison of the VES to its platform, the Gen X stent, with microporous
hydroxyapatite surface coating but without sirolimus. Patients were eligible if they
presented single de novo lesions in native coronary arteries with 3.0-3.5mm diameter
and ≤ 14mm in length. Primary endpoint was 9-month in-stent late loss and % of stent
obstruction. Lifelong AAS and 6-month clopidogrel were prescribed to all pts.
Results: A total of 75 patients were enrolled (50 treated with the DES). Baseline
characteristics included mean age of 57 years and 23% of diabetics, with no differences
between groups. RVD and lesion length were 2.67 ± 0.4mm and 14.0 ± 2.0mm.
Procedure success was obtained in all cases. Three patients (4.2%) presented non-Q
wave MI during hospitalization with no other MACE. After discharge, there were two
cases of TLR(one in each group) and no MI, death or stent thrombosis. At nine months,
the DES had a late loss of 0.39mm vs. 0.74mm with the non-eluted version (p=0.03).
By IVUS, % of stent obstruction was 9% with the DES vs. 17% with the BMS
(p<0.001).
Conclusion: The preliminary results of the Vestasync II trial demonstrate efficacy and
midterm safety of these novel polymer-free DES. Further long term assessment in more
complex cohorts is warranted.
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Background: Previous studies have revealed that stent diameter and length correlate
with restenosis or cardiovascular events after stenting. The purpose of this study was
to assess potential impact of stent size and length on neointimal hyperplasia (NIH)
after Resolute zotarolimus-eluting stent (ZES) implantation.
Methods: From the Stanford University IVUS Core Laboratory database, 151 de novo
coronary lesions treated with Resolute ZES were enrolled in this analysis. The lesions
were divided into 4 groups, based on stent volume index (cutoff: 6.0 mm3/mm, range:
3.2 to 13.0 mm3/mm) and total stent length (cutoff: 24 mm, range: 12 to 54 mm): Small-
Long (n=13), Large-Long (n=50), Small-Short (n=29), and Large-Short (n=59) stent
groups. Neointimal obstruction was calculated as neointima/stent volume. Cross-
sectional narrowing (CSN) was defined as neointima/stent area.
Results: Baseline patient characteristics were similar among the 4 groups. At 8-9
months, the 4 groups showed no significant difference in overall neointimal obstruction
(6.7±6.2, 4.6±3.9, 4.7±5.4, 3.6±5.2%, respectively, p=0.22) or mean NIH thickness.
Incidences of significant lumen encroachment (max CSN >50%) and late-acquired
incomplete stent apposition were also not statistically different. On the other hand,
significant differences were detected in max CSN among the groups. Overall,
regression analysis showed a positive correlation of max CSN with total stent length
(p=0.004), whereas a correlation with stent volume index did not reach statistical
significance (p=0.182).
Conclusion: Pooled IVUS analysis of RESOLUTE trials suggests total stent length
as the primary determinant of maximum lumen encroachment by neointima, rather
than stent size. In this population, however, this effect did not significantly impact the
overall amount of neointima or other clinically relevant IVUS variables.
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